Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Phoenix Financial Ltd. (REGN) drastically reduced its holdings in Regeneron Pharmaceuticals, Inc. by 75.3%, now owning just ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 29, 2025, to ...

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

Discover how 3 growth drivers are fuelling Peak India… and creating a rare window for potentially outsized gains for Indian ...

Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $57,109.53 today based on a price of $563.10 for REGN at the time of writing.

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...